Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Coegin Pharma

4.25 SEK

-0.93 %

Less than 1K followers

COEGIN

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-0.93 %
-4.28 %
-11.46 %
-38.23 %
+26.49 %
-7.61 %
-63.75 %
-77.15 %
-86.64 %

Coegin Pharma is a Swedish biotechnology company in commercial phase, developing science-based innovations for hair and skin. The company's patented ingredient for hair growth is now available in products sold through selected partners. A peptide for natural skin pigmentation is also in development with a planned launch in the near future. Coegin Pharma is headquartered in Lund.

Read more
Market cap
105.73M SEK
Turnover
27.95K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.2.
2026

Annual report '25

21.5.
2026

Interim report Q1'26

21.5.
2026

General meeting '26

All
Press releases
ShowingAll content types
Press release1/2/2026, 8:30 AM

Coegin Pharma provides an operational and strategic update

Coegin Pharma
Press release12/22/2025, 12:30 PM

Coegin Pharma appoints worldleading pigmentation and hair-biology expert Professor Desmond J. Tobin as Scientific Advisor

Coegin Pharma
Press release12/19/2025, 8:25 AM

Coegin Pharma completes first delivery of Follicopeptide products to Hårklinikken

Coegin Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release12/12/2025, 10:50 AM

Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents

Coegin Pharma
Regulatory press release11/27/2025, 8:45 AM

Coegin Pharma's Nomination Committee appointed for the 2026 Annual General Meeting

Coegin Pharma
Regulatory press release11/20/2025, 1:50 PM

Coegin Pharma AB (publ) publishes its quarterly report for the third quarter of 2025

Coegin Pharma
Press release11/14/2025, 1:42 PM

First Follicopeptide® powered product available for consumer pre-orders November 16 - a historic milestone for Coegin Pharma

Coegin Pharma
Press release11/6/2025, 1:45 PM

Coegin introduces new tailor-made Follicopeptide complementary product - launching early 2026

Coegin Pharma
Regulatory press release10/17/2025, 3:05 PM

Coegin Pharma enters collaboration with Hårklinikken - expands Follicopeptide® commercialization with a world renowned hair clinic brand

Coegin Pharma
Press release10/13/2025, 8:02 AM

Coegin Pharma establishes own agile production facility in Denmark - ensuring control, scalability, and cost efficiency for next phase of growth

Coegin Pharma
Regulatory press release9/17/2025, 12:30 PM

Coegin Pharma enters collaboration with Polish distributor Mercapharm - expands Follicopeptide® commercialisation to Poland

Coegin Pharma
Regulatory press release9/10/2025, 1:00 PM

Coegin Pharma enters collaboration with Swedish retailer Gents - kicks off next phase of Follicopeptide commercialisation

Coegin Pharma
Regulatory press release8/21/2025, 12:30 PM

Coegin Pharma AB (publ) publishes its Interim Report for the second quarter of 2025

Coegin Pharma
Press release8/20/2025, 6:30 AM

Coegin Pharma provides status update ahead of the upcoming commercialisation of its first Follicopeptide-based hair growth product

Coegin Pharma
Regulatory press release8/12/2025, 12:45 PM

Coegin Pharma changes language for company communication to English

Coegin Pharma
Press release7/2/2025, 6:30 AM

Coegin Pharma has reduced product cost by 80 percent - moving closer to the launch of Follicopeptide

Coegin Pharma
Regulatory press release5/22/2025, 11:30 AM

Communiqué from the Annual General Meeting of Coegin Pharma AB (publ)

Coegin Pharma
Regulatory press release5/22/2025, 6:35 AM

Coegin Pharma AB publishes its quarterly report for the first quarter of 2025

Coegin Pharma
Regulatory press release4/29/2025, 10:45 AM

Coegin Pharma AB publishes Annual Report for the financial year 2024

Coegin Pharma
Regulatory press release4/16/2025, 11:30 AM

Notice of Annual General Meeting in Coegin Pharma AB (publ)

Coegin Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.